Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Heron Therapeutics ( (HRTX) ) is now available.
On August 6, 2025, Heron Therapeutics entered into a Framework Agreement with Patheon Austria GmbH & Co KG and Thermo Fisher Scientific Inc. This agreement outlines the terms for Patheon to manufacture and supply specific quantities of products to Heron Therapeutics, with a commitment to purchase 38,400 kg of products by December 31, 2026. The agreement also includes ongoing stability studies and warehousing services, while terminating certain previous agreements between the parties.
The most recent analyst rating on (HRTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics’ overall score is driven by financial instability and technical weakness, despite positive strategic initiatives and earnings call sentiment. The company’s high leverage and negative equity are significant risks, but recent strategic moves and revenue growth provide some optimism.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutic products.
Average Trading Volume: 1,525,055
Technical Sentiment Signal: Strong Sell
Current Market Cap: $196.2M
For an in-depth examination of HRTX stock, go to TipRanks’ Overview page.